These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 24054012)
21. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma. Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM Am J Hematol; 2014 Jul; 89(7):726-31. PubMed ID: 24711255 [TBL] [Abstract][Full Text] [Related]
22. Metabolic activity measured by F-18 FDG PET in natural killer-cell lymphoma compared to aggressive B- and T-cell lymphomas. Chan WK; Au WY; Wong CY; Liang R; Leung AY; Kwong YL; Khong PL Clin Nucl Med; 2010 Aug; 35(8):571-5. PubMed ID: 20631501 [TBL] [Abstract][Full Text] [Related]
23. [Correlation between FDG PET /CT and the expression of glutl and ki-67 antigen in esophageal cancer]. Mu DB; Wang SP; Yang WF; Fu Z; Chen XX; Sun XR; Yu JM Zhonghua Zhong Liu Za Zhi; 2007 Jan; 29(1):30-3. PubMed ID: 17575690 [TBL] [Abstract][Full Text] [Related]
24. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma. Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082 [TBL] [Abstract][Full Text] [Related]
25. Correlation of Mitamura K; Yamamoto Y; Norikane T; Hatakeyama T; Okada M; Nishiyama Y Ann Nucl Med; 2018 Nov; 32(9):627-633. PubMed ID: 30032455 [TBL] [Abstract][Full Text] [Related]
26. Utilization of 18F-FDG PET/CT as a staging tool in patients with newly diagnosed lymphoma. Cho SF; Chang CC; Liu YC; Chang CS; Hsiao HH; Liu TC; Huang CT; Lin SF Kaohsiung J Med Sci; 2015 Mar; 31(3):130-7. PubMed ID: 25744235 [TBL] [Abstract][Full Text] [Related]
27. Prognostic value of tumor 18F-FDG uptake in patients with untreated extranodal natural killer/T-cell lymphomas of the head and neck. Suh C; Kang YK; Roh JL; Kim MR; Kim JS; Huh J; Lee JH; Jang YJ; Lee BJ J Nucl Med; 2008 Nov; 49(11):1783-9. PubMed ID: 18927319 [TBL] [Abstract][Full Text] [Related]
28. [Positron emission tomography with 18F-FDG compared with proliferative activity of tumor cells in different subtypes of non-Hodgkin lymphoma]. Tiutin LA; Khodzsibekova MM; Pozharisskiĭ KM; Mukhina MS; Kostenikov NA; Il'in NV Vopr Onkol; 2011; 57(6):748-52. PubMed ID: 22416392 [TBL] [Abstract][Full Text] [Related]
29. Utility of 18F-FDG PET/CT for staging NK/T-cell lymphomas. Wu HB; Wang QS; Wang MF; Li HS; Zhou WL; Ye XH; Wang QY Nucl Med Commun; 2010 Mar; 31(3):195-200. PubMed ID: 20009963 [TBL] [Abstract][Full Text] [Related]
30. The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma. Karantanis D; Subramaniam RM; Peller PJ; Lowe VJ; Durski JM; Collins DA; Georgiou E; Ansell SM; Wiseman GA Clin Lymphoma Myeloma; 2008 Apr; 8(2):94-9. PubMed ID: 18501102 [TBL] [Abstract][Full Text] [Related]
32. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes. Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992 [TBL] [Abstract][Full Text] [Related]
33. [Correlation and Influencing Factors of SUVmax and Ki-67 in Non-Hodgkin Lymphoma]. Li J; Zhao M; Yuan L; Liu Y; Ma N Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):136-140. PubMed ID: 35123616 [TBL] [Abstract][Full Text] [Related]
34. Diagnostic value of 18F-FDG PET/CT for cutaneous extranodal natural killer/T-cell lymphoma, nasal type. Liu C; Zhang Y; Zhang Y; Wang M; Liu R; Liu X; Hu S Nucl Med Commun; 2016 May; 37(5):446-52. PubMed ID: 26657218 [TBL] [Abstract][Full Text] [Related]
35. Correlating metabolic activity with cellular proliferation in follicular lymphomas. Tang B; Malysz J; Douglas-Nikitin V; Zekman R; Wong RH; Jaiyesimi I; Wong CY Mol Imaging Biol; 2009; 11(5):296-302. PubMed ID: 19430847 [TBL] [Abstract][Full Text] [Related]
36. Correlation of ¹⁸F-FDG PET activity with expressions of survivin, Ki67, and CD34 in non-small-cell lung cancer. Han B; Lin S; Yu LJ; Wang RZ; Wang YY Nucl Med Commun; 2009 Nov; 30(11):831-7. PubMed ID: 19734817 [TBL] [Abstract][Full Text] [Related]
37. The prevalence and clinical significance of (18) F-2-fluoro-2-deoxy-D-glucose (FDG) uptake in the thyroid gland on PET or PET-CT in patients with lymphoma. Lin M; Wong C; Lin P; Shon IH; Cuganesan R; Som S Hematol Oncol; 2011 Jun; 29(2):67-74. PubMed ID: 20635328 [TBL] [Abstract][Full Text] [Related]
38. Expression levels of apoptosis-related proteins and Ki-67 in nasal NK / T-cell lymphoma. Yasuda H; Sugimoto K; Imai H; Isobe Y; Sasaki M; Kojima Y; Nakamura S; Oshimi K Eur J Haematol; 2009 Jan; 82(1):39-45. PubMed ID: 18778369 [TBL] [Abstract][Full Text] [Related]
39. [The diagnostic value of (18)F-FDG PET-CT imaging in patients with primary extranodal lymphoma]. Dang N; Xu W; Song X; Dai D; Zhu L; Zhu X; Ma W; Wang J Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):35-9. PubMed ID: 24602729 [TBL] [Abstract][Full Text] [Related]
40. The feasibility of 18F-fluorodeoxyglucose-positron emission tomography uptake as a prognostic factor for paranasal sinus malignancy. Seol JH; Kim J; Lee JD; Lee JG; Yoon JH; Kim CH Am J Rhinol Allergy; 2013; 27(2):118-22. PubMed ID: 23562200 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]